The Importance of Establishing Baseline Disease Characteristics in Myeloma Diagnosis and Management
Release Date: November 11, 2015
Expiration Date: November 11, 2016
Expected time to complete this activity as designed: 30 minutes
There are no fees for participating in or receiving credit for this online activity.
Plasma cell dyscrasias are part of a spectrum of conditions which range in their severity from monoclonal gammopathy of unknown significance (MGUS), smoldering multiple myeloma (SMM), and the more advanced stage of active or overt multiple myeloma (MM). Each of these entities pose different potential outcomes for patients who have them and, therefore, an accurate diagnosis and prognosis is essential in establishing treatment goals and in retrospective assessment of patient outcomes as a consequence of specific interventions. Both the National Comprehensive Cancer Network (NCCN) and the International Myeloma Working Group (IMWG) recommend a battery of diagnostic and prognostic tests for any patient suspected of having myeloma. These tests are designed to translate clinical insight into a formal diagnosis using the universally accepted IMWG diagnostic criteria. Of importance, these criteria have recently been updated to include patients who would previously have been diagnosed with SMM in the absence of CRAB criteria but who have biomarkers of malignancy that now place them in the category of having active or overt MM. A number of additional recommendations have recently been made by the IMWG regarding staging and risk-stratification with the introduction of the Revised International Staging System (R-ISS), which should be universally adopted in practice, as well as recommendations regarding the care of geriatric patients. Changes to the uniform response criteria and further recommendations regarding the monitoring of bone disease are anticipated in the near future. Presenting a challenge to the health care community, neither academic or community-based practitioners are consistently and fully conducting the IMWG/NCCN recommended baseline work-up tests according to a recent study report from the Connect MM Registry, the first and largest observational, noninterventional, prospective registry of patients newly diagnosed with MM in the United States. Analysis of the data reveals that a number of essential tests that are required to diagnose, stage, and prognose MM are not being conducted consistently, and these deficiencies are likely to significantly hinder the appropriate diagnosis, staging, and prognosis of patients under the new recommendations.
Join our world-leading Managing Myeloma team expert faculty members, Dr. Kenneth Anderson, chair of the NCCN Committee for Multiple Myeloma, and Dr. Brian GM Durie, chairman of the International Myeloma Foundation (IMF) Board and IMWG, in a discussion regarding the importance of establishing baseline disease characteristics in myeloma diagnosis and management.
This activity is designed for physicians, pharmacists, physician assistants, and other health care professionals who have an interest in enhancing their clinical skills in the management of multiple myeloma.
Upon completion of this educational activity, participants should be able to:
- Recognize the specific NCCN and IMWG diagnostic updated criteria and the recommended associated work up for the diagnosis and prognosis of patients with suspected myeloma
- Recognize consequences of missing tests and/or failure to implement criteria and perform NCCN and IMWG recommended diagnostic and prognostic tests in their entirety
- Propose strategies to improve adherence to NCCN and IMWG recommended diagnostic and prognostic testing for patients suspected of having myeloma
The Importance of Establishing Baseline Disease Characteristics in Myeloma Diagnosis and Management – Kenneth C. Anderson, MD, and Brian G.M. Durie, MD
Instructions for Participation and Credit
This activity is eligible for credit through November 11, 2016. After this date, this activity will expire and no further credit will be awarded.
- Read the target audience, learning objectives, and faculty disclosures.
- You may be asked to complete a short pre-test before accessing the educational content. This must be completed in order to move forward in the activity.
- Complete the educational content as designed.
- Complete the post-test. To receive a certificate, you must receive a passing score of 70%.
- Complete the activity evaluation survey to provide feedback and information useful for future programming.
- Certificates for CME credit may be printed immediately after successfully completing the post-test and activity evaluation. Pharmacist credit will be uploaded to CPE Monitor 4 weeks following receipt of a completed, qualified form.
Kenneth C. Anderson, MD
Kraft Family Professor of Medicine
Harvard Medical School
Chief, Division of Hematologic Neoplasia
Director, Jerome Lipper Multiple Myeloma Center
Director, LeBow Institute for Myeloma Therapeutics
Dana-Farber Cancer Institute
Dr. Kenneth Anderson graduated from Johns Hopkins Medical School, trained in internal medicine at Johns Hopkins Hospital, and completed hematology, medical oncology, and tumor immunology training at the Dana-Farber Cancer Institute. He is the Kraft Family Professor of Medicine at Harvard Medical School; and serves as chief of the Division of Hematologic Neoplasia, director of the LeBow Institute for Myeloma Therapeutics and Jerome Lipper Multiple Myeloma Center, and vice chair of the Joint Program in Transfusion Medicine at Dana-Farber Cancer Institute.
Dr. Anderson serves as chair of the NCCN Multiple Myeloma Clinical Practice Guidelines Committee; as a Cancer and Leukemia Group B Principal Investigator; on the Board of Scientific Advisors of the International Myeloma Foundation; and is on the Board of Directors and Chair of both the Scientific Advisory Board of the Multiple Myeloma Research Foundation and the Steering Committee of the Multiple Myeloma Research Consortium. Dr. Anderson has published more than 350 original articles, 250 chapters, has edited multiple textbooks on both multiple myeloma and on transfusion medicine, and was named editor in chief of Clinical Cancer Research. In addition, he is a Doris Duke Distinguished Clinical Research Scientist and has received numerous other awards.
Over the last two decades, Dr. Anderson has focused his translational research studies on B-cell malignancies, especially multiple myeloma. His team led both preclinical and clinical trials of the novel proteasome inhibitor bortezomib, as well as lenalidomide. His research offers great promise to improve patient outcome in hematologic malignancies and solid tumors.
Brian G. M. Durie, MD
International Myeloma Foundation
Cedars-Sinai Medical Center
Los Angeles, California
Dr. Brian Durie received his medical degree from the University of Edinburgh Medical School, Scotland, and completed his residencies and fellowships at the Mayo Clinic and the University of Minnesota. Dr. Durie, a clinical expert in multiple myeloma, is an attending physician at the Cedars-Sinai Medical Center, Los Angeles. In addition, he is the senior advisor for hematologic malignancies, and national program director for multiple myeloma and related disorders for Aptium Oncology.
Dr. Durie is board certified by the American Board of Internal Medicine with subspecialties in both medical oncology and hematology. He founded and now chairs the International Myeloma Foundation and serves on its Scientific Advisory Board. Dr. Durie, along with Dr. Sydney Salmon, co-created the Durie/Salmon Staging System, which is used worldwide for evaluating patients with myeloma. He is the recipient of numerous honors and awards for excellence and is also a Marquis member of “Who's Who in America” and “The Best Doctors in America.”
Dr. Durie has written over 400 research papers, 16 book chapters, and five books; he has published research manuscripts in both basic research journals as well as major clinical journals such as The New England Journal of Medicine. Dr. Durie is also an international patent holder for scintillation autoradiography.
Accreditation Statement: MediCom Worldwide, Inc. is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Designation Statement: MediCom Worldwide, Inc. designates this enduring material for a maximum of 0.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
MediCom Worldwide, Inc. is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. This activity is acceptable for 0.5 contact hours of Continuing Education Credit. Universal Activity Number: 827-0000-15-050-H01-P. Knowledge-based CPE activity.
In order for CPE Monitor to authenticate credit, pharmacists/technicians must provide their e-Profile ID number from NABP and date of birth (in MMDD format) when registering for a CPE program. Please make sure to provide this information in your Member Profile accessed through the Member Center on the home page of this site.
As an organization accredited by the Accreditation Council for Continuing Medical Education (ACCME), Accreditation Council for Pharmacy Education (ACPE) and California State Board of Registered Nursing, MediCom Worldwide, Inc. requires everyone who is a position to control the content of an educational activity to disclose all relevant financial relationships with any commercial interest. The ACCME defines “relevant financial relationships” as financial relationships in any amount, occurring within the past 12 months, including financial relationships of a spouse or life partner, that could create a conflict of interest. Accordingly, the following disclosures were made.
Dr. Kenneth Anderson has received honoraria related to formal advisory activities and as a consultant from Bristol-Myers Squibb Company, Celgene Corporation, Gilead, and Takeda Oncology. He is scientific founder and owns significant holdings in Acetylon Pharmaceuticals, Inc. and OncoPep
Dr. Brian Durie has disclosed no relevant financial relationships.
Planning Committee Disclosures
The individuals listed below from MediCom Worldwide, Inc. reported the following for this activity: Joan Meyer, RN, MHA, executive director, and Eugene R. Tombler, PhD, FACME, medical director, oncology, have no relevant financial relationships.
Peer Reviewer Disclosure
In accordance with MediCom Worldwide, Inc. policy, all content is reviewed by external independent peer reviewers for balance, objectivity and commercial bias. The peer reviewers have no relevant financial relationships to disclose.
Off-Label Disclosures/Investigational Disclosures
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The opinions expressed in the educational activity are those of the faculty. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings. Further, attendees/participants should appraise the information presented critically and are encouraged to consult appropriate resources for any product or device mentioned in this program.
Dr. Anderson and Dr. Durie have indicated that they do not intend to discuss off-label uses of drugs, mechanical devices, biologics or diagnostics approved by the US Food and Drug Administration (FDA) for use in the US.
Dr. Anderson and Dr. Durie have indicated that they do not intend to discuss investigational drugs, mechanical devices, biologics or diagnostics not approved by the FDA for use in the US.
MediCom Worldwide, Inc. requires Internet Explorer® version 9.0 or higher, the latest version of Google Chrome, or the latest version of Safari, a computer running Windows® Vista, Windows® 7, or Mac OS X, 512MB of RAM or greater, 1.5 GHZ or faster processor, and a screen resolution of 1024x768 or higher. Certain educational activities may require additional software to view. These activities will be marked with the information and/or links to the required software. That software may include Adobe® Flash® Player, Adobe® Acrobat®, Windows Media® Player, and/or Microsoft® Silverlight™.
If you have any questions or concerns regarding this activity, please contact MediCom Worldwide, Inc. at 1-800-408-4242 or email us at firstname.lastname@example.org.
Provided by MediCom Worldwide, Inc.
This activity is supported by educational grants from Takeda Oncology and Celgene Corporation.
©2015 MediCom Worldwide, Inc., 101 Washington St., Morrisville, PA 19067, 800-408-4242.
No portion of this material may be copied or duplicated without the expressed permission of MediCom Worldwide, Inc.